Leiomyomatosis peritonealis disseminata with aromatase cytochrome P450 expression in a postmenopausal woman: a case study with literature review

Purpose of Investigation: The authors aimed to assess the hypothesis that leiomyomatosis peritonealis disseminata (LPD) in a postmenopausal woman had autocrine estrogen secretion abilities. Materials and Methods: A 73-year-old woman presented with a bulky tumour in the peritoneal cavity. The pathological diagnosis was LPD or sarcoma of unknown origin. Medroxyprogesterone acetate (MPA) and GnRH analogue therapies were effective, but a tumour mass was confirmed with rapid growth immediately after the cessation of treatment and led to her death from intra-tumour haemorrhage. The authors evaluated the mechanism of tumour using immunostaining for aromatase cytochrome P450. Results: The tumour showed high expression of aromatase. The immunostaining patterns of estrogen receptor (ER), progesterone receptor (PgR), and aromatase were similar to those of a premenopausal leiomyoma. Conclusion: It is likely that the tumour had the autocrine ability to secrete estrogen and that tumour growth resumed because of a flare-up caused by the downregulation of hormonal therapies.

Leiomyomatosis peritonealis disseminata; Postmenopause; Malignant, Estradiol; Aromatase immunostaining.

[1] Tavassoli F.A., Norris H.J.: “Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations”. Int. J. Gynecol. Pathol., 1982, 1, 59.

[2] Fujii S., Nakashima N., Okamura H., Takenaka A., Kanzaki H., Okuda Y., et al.: “Progesterone-induced smooth muscle-like cells in the subperitoneal nodules PRoduced by estrogen. Experimental approach to leiomyomatosis peritonealis disseminata”. Am. J. Obstet. Gynecol., 1981, 139, 164.

[3] Willson J.R., Pearle A.R.: “Multiple peritoneal leiomyomas associated with a granulosa-cell tumor of the ovary”. Am. J. Obstet. Gynecol., 1952, 64, 204.

[4] Bekkers R.L., Willemsen W.N., Schijf C.P., Massuger L.F., Bulten J., Merkus J.M.: “Leiomyomatosis peritonealis disseminata: does malignant transformation occur? A literature review”. Gynecol. Oncol., 1999, 75, 158.

[5] Butnor K.J., Burchette J.L., Robboy S.J.: “Progesterone receptor activity in leiomyomatosis peritonealis disseminata”. Int. J. Gynecol. Pathol., 18, 259.

[6] Yamaguchi T., Imamura Y., Yamamoto T., Fukuda M.: “Leiomyomatosis peritonealis disseminata with malignant change in a man”. Pathol. Int., 2003, 53, 179.

[7] Takeda T., Masuhara K., Kamiura S.: “Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor”. Obstet. Gynecol., 2008, 112, 491.

[8] Kökçü A., Alvur Y., Bariş Y.S., Kuşkonmaz I.: “Leiomyomatosis peritonealis disseminata”. Acta Obstet. Gynecol. Scand., 1994, 73, 81.

[9] Komatsu M., Tsuchiya S., Kuroda T.: “Leiomyomatosis peritonealis disseminata occurring in a postmenopausal woman: report of a case”. Surg. Today, 1996, 26, 7000.

[10] Nigojevic S., Kapural L., Scukanec-Spouar M., Andelinovic S., Jankovic S., Jukic D.M., Primorac D.: “Leiomyomatosis peritonealis disseminata in a postmenopausal woman”. Acta Obstet. Gynecol. Scand., 1997, 76, 893.

[11] Strinić T., Kuzmić-Prusac I., Eterović D., Jakić J., Sćukanec M.: “Leiomyomatosis peritonealis disseminata in a postmenopausal woman”. Arch. Gynecol. Obstet., 2000, 264, 97.

[12] Nguyen G.K.: “Disseminated leiomyomatosis peritonealis: report of a case in a postmenopausal woman”. Can. J. Surg., 1993, 36, 46.

[13] Mansour F., Darai E., Felgeres A., Meicler P., Pinet C., Colau J.C.: “Disseminated peritoneal leiomyomatosis. Apropos of a case”. Rev Fr. Gynecol. Obstet., 1992, 87, 431.

[14] Brumback R.A., Brown B.S., Sobie P., Shapiro M.J., Wallinga H.A.: “Leiomyomatosis peritonealis disseminata”. Surgery. 1985, 97, 707.

[15] Rajab K.E., Aradi A.N., Datta B.N.: “Postmenopausal leimyomatosis peritonealis disseminata”. Int. J. Gynecol. Obstet., 2000, 68, 271.

[16] Hiraoka K., Nagaoka M., Yamabe K., Fujita S., Michiura T.: “A case of leiomyomatosis peritonialis disseminata”. J. Jpn. Surg. Assoc., 2013, 74, 1375.

[17] Raspagliesi F., Quattrone P., Grosso G., Cobellis L., Di Re E.: “Malignant degeneration in leiomyomatosis peritonealis disseminata”. Gynecol. Oncol., 1996, 61, 272.

[18] Tun A.M., Tun N.M., Zin Thein K., Naing E.E., Giashuddin S., Shulimovich M.: “A rare concurrence of leiomyomatosis peritonealis disseminata, leiomyosarcoma of the pelvis and leiomyomatous nodule of the liver”. Case Rep. Oncol. Med., 2016, 2016, 3025432.

[19] Sharma P., Chaturvedi K.U., Gupta R., Nigam S.: “Leiomyomatosis peritonealis disseminata with malignant change in a post-menopausal woman”. Gynecol. Oncol., 2004, 95, 742.

[20] Lin Y.C., Wei L.H., Shun C.T., Cheng A.L., Hsu C.H.: “Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy”. Oncology, 2009, 76, 55.

[21] Parente J.T., Levy J., Chinea F., Espinosa B., Brescia M.J.: “Adjuvant surgical and hormonal treatment of leiomyomatosis peritonealis disseminata. A case report”. J. Reprod. Med., 1995, 40, 468.

[22] Hales H.A., Peterson C.M., Jones K.P., Quinn J.D.: “Leiomyomatosis peritonealis disseminata treated with a gonadotropin-releasing hormone agonist. A case report”. Am. J. Obstet. Gynecol., 1992, 167, 515.

[23] Sumitani H., Shozu M., Segawa T., Murakami K., Yang H.J., Shimada K., Inoue, M.: “In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism”. Endocrinology, 2000, 141, 3852.

[24] Ishikawa H., Reierstad S., Demura M., Rademaker A.W., Kasai T., Inoue M., et al.: “High aromatase expression in uterine leiomyoma tissues of African-American women”. J. Clin. Endocrinol. Metab., 2009, 94, 1752.

[25] Ishihara H., Kitawaki J., Kado N., Koshiba H., Fushiki S., Honjo H.: “Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas”. Fertil. Steril., 2003, 79, 735.